Latest research news

Breakthrough in Huntington's disease research 

A research team at University College London’s Huntington’s Disease Centre investigating the first potential treatment for Huntington’s disease has announced “results of ground-breaking importance for Huntington’s disease patients and families”.

An experimental drug, known as an 'antisense oligonucleotide' (ASO), has proven to safely lower the levels of the toxic protein which causes Huntington's

Read more about this breakthrough


Ask the expert: Your questions answered

Dr Ed Wild, our scientific adviser and co-founder of Huntington's disease research website HDBuzz, answers your questions about the recent breakthrough in the Huntington's disease antisense drug trial.

Read the Q&A

Video: Understanding antisense research

When the news broke in November 2017 about the early findings from the Huntington’s disease antisense drug trial, it raised lots of questions for Huntington’s communities in the UK and around the world.

Our scientific adviser, Dr Ed Wild, talks to Huntington’s family member Paula Meir about the news. They discuss what the research means for people with Huntington’s, how the research is carried out and who is involved with it, and how the research teams recruit participants for the research trials.  

You can find out more about the Huntington’s disease research team from University College London (UCL) and their work at hdresearch.ucl.ac.uk

Find out about executive coach and author Paula Meir at www.paulameir.com

Keep up to date with research

Find out the latest news in the world of Huntington’s disease research by visiting HD Buzz - a website full of information about research written by scientists in plain language.

New to Huntington’s disease research?

If you’ve never visited HD Buzz before take a look at this page for an overview of HD Buzz and Huntington’s disease research.

Confused by the jargon?

Find out about the scientific words and phrases used in Huntington’s disease research in the useful HD Buzz glossary.